PhD Student Retreat 2025: Bridging Disciplines, Building Teams
16.05.2025A group of 18 PhD students of the Leibniz Institute for Immunotherapy (LIT) attended this year’s PhD retreat in the Bavarian Forest.
News
The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.
Showing
Leibniz Institute for Immunotherapy (LIT) expands research team with Dr. Leo Scheller
15.05.2025We are excited to welcome Dr. Leo Scheller to our team. He will head the new research group “Structural Biochemistry” at the LIT, which develops synthetic receptors and protein therapeutics to improve the safety and efficacy of immunotherapies.
Speed Dating with Science: LIT researchers take part in “Book a Scientist”
13.05.2025“Book a Scientist” is a conversation format in which interested parties can “book” 25-minute one-on-one conversations with Leibniz scientists on fixed topics according to the speed dating principle.
Network|City Event at the Leibniz Institute for Immunotherapy (LIT)
28.03.2025Over 30 interested citizens of Regensburg, along with members of the CSU parliamentary group and Mayor Dr. Astrid Freudenstein, visited the Leibniz Institute for Immunotherapy on Tuesday, March 25.
New LIT Cooperation Groups: The LIT is expanding
27.03.2025The LIT is expanding its clinical cooperations and welcomes several new LIT Cooperation Groups with their staff. This cooperational format aims to foster scientific synergies and clinical translation with groups that address complementary clinical topics in immunomedicine.
LIT Scientists receive ScaleReady G-Rex® Grant
13.03.2025Dr. Dr. Roland Schelker, head of the newly formed Translation Group “T-Cell Fitness” at the LIT and hematology/oncology medical specialist at the University Hospital Regensburg, receives a 75,000 USD G-Rex® Grant by ScaleReady LLC. Pedro Noronha, Research Technician in the LIT Division of Functional Immune Cell Modulation, was intensively involved in the grant application process.
The National Strategy for Gene and Cell-based Therapies Funds the University Hospital Regensburg and the Leibniz Institute for Immunotherapy to Advance Cutting-Edge T Cell Therapy for Sarcoma Patients
06.03.2025Researchers at the University Hospital Regensburg and the Leibniz Institute for Immunotherapy (LIT) are embarking on an innovative project, ESOSTEM155, aimed at transforming T cell-based cancer therapies. This initiative has been awarded a two-year grant of 460,000 EUR from the National Strategy for Gene and Cell-based Therapies (GCT) funding program.
LIT Postdoc Retreat 2025
10.02.2025In January 2025 the first LIT Postdoc Retreat took place in Regensburg.
LIT scientists give insights in T cell therapy for clinicians
06.02.2025LIT scientists Dr. Astrid Holzinger, Dr. Markus Barden and Prof. Hinrich Abken give an overview on CARs, TRUCKS and the next generation of T cell therapy in the journal JATROS Hämatologie & Onkologie.
Scientist Roland C. Schelker earns his second doctorate (PhD) with summa cum laude at the LIT
03.02.2025The Leibniz Institute for Immunotherapy (LIT) is pleased to announce the successful completion of Dr. Roland C. Schelker’s second doctoral degree.
